Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04459416 · ClinicalTrials.gov registry record · Phase 3
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma
A Phase 3 study of Multiple Myeloma and Non-Hodgkin Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 3
- Development phase
- 299
- Enrollment target
- 3
- Study locations
NCT04459416: Active Phase 3 study of Multiple Myeloma and Non-Hodgkin Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04459416 is a Phase 3 study of Multiple Myeloma and Non-Hodgkin Lymphoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 299 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (45% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04459416, a Phase 3 study of Multiple Myeloma and Non-Hodgkin Lymphoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 299 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to find out whether acupuncture treatments can reduce the need for opioid medication when managing pain caused by chemotherapy. The study will compare the effects of adding acupuncture to usual pain management with those of usual pain management alone, in reducing opioid use by relieving pain. Researchers also want to find out more about the effects of acupuncture treatments on other symptoms caused by cancer treatments and quality of life.
Primary Outcome
at a given time divided by the total number of patients randomized to that group at Day 7) by review of medication records and urine drug test
Conditions Studied
Interventions
- OTHER Acupuncture
- OTHER Assessments
- DRUG opioid
Study Locations (3)
Washington
- Fred Hutchinson Cancer Research Center - Seattle
- Seattle Cancel Care Alliance (Data Collection Only) - Seattle
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 299 participants |
| Start Date | 2020-06-30 |
| Est. Completion | 2026-06 |
| Phase | Phase 3 |
What the registry record for NCT04459416 still lists
NCT04459416 is an interventional study that assigns participants to a tested intervention. The registered 299 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (45% lower).
The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Acupuncture is the first listed.
NCT04459416 reports a single indexed study location in Washington, New York.
Frequently Asked Questions
What is clinical trial NCT04459416 about?
NCT04459416 is a clinical study titled "Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma". The purpose of this study is to find out whether acupuncture treatments can reduce the need for opioid medication when managing pain caused by chemotherapy. The study will compare the effects of adding acupuncture to usual pain management with those of usual pain management alone, in reducing opioid...
What is the current status of trial NCT04459416?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 299 participants. The study started on 2020-06-30. Estimated completion is 2026-06.
What conditions does trial NCT04459416 study?
This clinical trial studies the following conditions: Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease.
What interventions are being tested in trial NCT04459416?
The interventions under investigation include: Acupuncture (OTHER), Assessments (OTHER), opioid (DRUG).
Who is sponsoring clinical trial NCT04459416?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04459416 being conducted?
This trial has 3 study locations across New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04459416's enrollment target sits among peer trials
299 79th of 438 higher than 360 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI